199 related articles for article (PubMed ID: 25713719)
21. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Yamada Y; Washida H; Tozawa K; Honma H; Kang K
Hinyokika Kiyo; 1994 Jul; 40(7):575-9. PubMed ID: 8085517
[TBL] [Abstract][Full Text] [Related]
22. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
23. Peritoneal and pulmonary tuberculosis following intravesical administration of Bacillus Calmette-Guérin for bladder cancer.
Uematsu R; Teishima J; Sakata H; Mita Y; Yoshii T; Tashiro Y; Yao A; Nakamura I
Int Cancer Conf J; 2023 Jul; 12(3):221-225. PubMed ID: 37251014
[TBL] [Abstract][Full Text] [Related]
24. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
[TBL] [Abstract][Full Text] [Related]
25. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
Ng KL; Chua CB
Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
27. A case of disseminated
Nishimura M; Okumura M; Takemasa T; Yoshiyama T; Tanaka Y; Saotome M; Ohta K
Respir Med Case Rep; 2023; 45():101902. PubMed ID: 37538979
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature.
Alvarez-Múgica M; Gómez JM; Vázquez VB; Monzón AJ; Rodríguez JM; Robles LR
J Med Case Rep; 2009 Sep; 3():7323. PubMed ID: 19918272
[TBL] [Abstract][Full Text] [Related]
29. Microscopic detection of bacillus Calmette-Guérin mycobacteria in bladder biopsy using fluorescence
Loukil A; Baron SA; Argemi X; Maubon T; Eldin C
New Microbes New Infect; 2021 Jan; 39():100826. PubMed ID: 33425363
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
31. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
32. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
33. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
34. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
35. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.
Lamm DL; van der Meijden PM; Morales A; Brosman SA; Catalona WJ; Herr HW; Soloway MS; Steg A; Debruyne FM
J Urol; 1992 Mar; 147(3):596-600. PubMed ID: 1538436
[TBL] [Abstract][Full Text] [Related]
36. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
[TBL] [Abstract][Full Text] [Related]
37. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
38. Bacillus Calmette-Guérin Packaged for Percutaneous Vaccination Can Be Safely Used for Intravesical Instillation in Patients with Urothelial Carcinoma of the Bladder.
Masic S; Srivastava A; Kloth D; Needleman R; Bloom E; Uzzo RN; Amoroso C; Lee R; Greenberg R; Smaldone M; Viterbo R; Joshi S; Chen DYT; Uzzo RG; Kutikov A
Urol Pract; 2020 Nov; 7(6):487-489. PubMed ID: 37287176
[TBL] [Abstract][Full Text] [Related]
39. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.
Rawls WH; Lamm DL; Lowe BA; Crawford ED; Sarosdy MF; Montie JE; Grossman HB; Scardino PT
J Urol; 1990 Dec; 144(6):1328-30. PubMed ID: 2231917
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin.
Peyromaure M; Ravery V
Expert Rev Anticancer Ther; 2002 Dec; 2(6):667-70. PubMed ID: 12503212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
